ENDRA Life Sciences stockholders approve reverse stock split; board sets ratio at 1-for-35

ENDRA Life Sciences Inc.

Stockholders approved reverse stock split at Special Meeting on Oct 28, 2024 with 4,241,540 for, 2,792,189 against, 18,228 abstain.
Board of Directors subsequently approved a ratio of 1-for-35 for the reverse stock split.
Reverse split ratio may be implemented at board's discretion within one year of meeting date; all other proposed ratios abandoned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.